Q-omics provides the consensus-scored LHX9 profile across patient tissues and cancer cell-line models. LHX9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LHX9 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, LHX9 RNA expression shows 9,766 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LUAD, and TGCT as cancer lineages where LHX9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LHX9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LHX9 survival associations across molecular data types. LHX9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LHX9 RNA expression–survival associations across cancer types. High LHX9 expression shows unfavorable associations in UCEC, KIRC, ACC, MESO and SARC, but favorable associations in HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LHX9 RNA expression.
This table summarizes LHX9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LHX9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LHX9 shows lower tumor expression in LUAD, LUSC and THCA and higher tumor expression in HNSC, KICH and BRCA. The LUAD box plot shows higher LHX9 RNA expression in normal versus tumor tissue (log2 FC = −0.934, t-test p < 0.001).
This table shows molecular features associated with LHX9 in patient tissues and cancer cell lines. In patient samples, LHX9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LHX9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
